Blog Cas9 Antibody Cas9 Cell Line Cas9 Dna Sequence Cas9 Enzyme Cas9 Lentivirus Cas9 Mrna Cas9 Nickase
Molybdenum Trioxide purified Antimony Trioxide extrapurified AR Molybdenum Trioxide extrapurified AR Pyridine-Sulfur Trioxide Complex Lead Titanium Trioxide Sulfur Trioxide Pyridine Complex
Acquired genetic mutations can confer resistance to arsenic trioxide (ATO) within the remedy of acute promyelocytic leukemia (APL). Nonetheless, such resistance-conferring mutations are uncommon and don’t clarify most illness recurrence seen within the clinic.
Now we have generated secure ATO-resistant promyelocytic cell strains which are additionally much less delicate to ATRA and the mix of ATO and ATRA in comparison with the delicate cell line.
Characterization of those in-house generated resistant cell strains confirmed important variations in immunophenotype, drug transporter expression, anti-apoptotic protein dependence, and PML-RARA mutation. Gene expression profiling revealed outstanding dysregulation of the mobile metabolic pathways in these ATO resistant APL cell strains.
Glycolytic inhibition by 2-DG was enough and corresponding to the usual of care (ATO) in focusing on the delicate APL cell line. 2-DG was additionally efficient within the in vivo transplantable APL mouse mannequin; nevertheless, it didn’t have an effect on the ATO resistant cell strains. In distinction, the resistant cell strains had been considerably affected by compounds focusing on the mitochondrial respiration when mixed with ATO, regardless of the ATO resistance-conferring genetic mutations or the sample of their anti-apoptotic protein dependency.
Our information exhibit that the addition of mitocans together with ATO can overcome ATO resistance. We additional present that this mixture has the potential within the remedy of non-M3 AML and relapsed APL. The interpretation of this strategy within the clinic must be explored additional.
Colorimetric Comparability of Inside Bleaching with and with out Eradicating Mineral Trioxide Mixture (MTA) on Induced Coronal Tooth Discoloration by MTA
This examine aimed to colorimetric comparability of inner bleaching with and with out eradicating mineral trioxide combination (MTA) on induced coronal tooth discoloration by MTA cement. On this experimental examine, twenty human tooth had been ready.
An OrthoMTA barrier was positioned 1 mm beneath the CEJ. The tooth had been restored with composite resin and had been positioned within the ageing accelerator machine. Then, the specimens had been divided into two teams (n = 10); in group A, a part of the OrthoMTA was eliminated and the glass ionomer was positioned on the OrthoMTA, and in group B, the OrthoMTA remained intact. Inside bleaching was carried out 5 instances in 6-day intervals utilizing 37% carbamide peroxide gel.
Coloration dedication was carried out in 5 phases: baseline, after OrthoMTA discoloration, earlier than OrthoMTA elimination, after OrthoMTA elimination, and after bleaching remedy periods. In group A, eight specimens reached to ∆E < 3.Three after 2 instances inner bleaching remedy, and in group B, 5 specimens reached to ∆E < 3.Three with nearly Three bleaching periods (p > 0.05).
Moreover, 5 specimens reached to the preliminary colour (baseline) after bleaching remedy, Four specimens in group A and 1 specimen in group B. After OrthoMTA elimination, 2 specimens in group A reached to ∆E < 3.3. There was no important distinction between teams with or with out OrthoMTA elimination (p=0.06). Though, the specimens with OrthoMTA elimination required fewer bleaching remedy periods, and the imply worth of ∆E was decrease on this group.
Iridium in Tungsten Trioxide Matrix as an Environment friendly Bi-Purposeful Electrocatalyst for General Water Splitting in Acidic Media
Electrocatalytic water splitting in acidic media is a promising technique for grid scale manufacturing of hydrogen utilizing renewable power, however challenges nonetheless exist within the growth of superior catalysts with each excessive exercise and stability.
Herein, it’s reported that iridium doped tungsten trioxide (Ir-doped WO3 ) with arrayed construction and confined Ir websites is an environment friendly and sturdy bi-functional catalyst for general acidic water splitting. A low overpotential (258 mV) is required to realize an oxygen evolution response present density of 10 mA cm-2 in 0.5 m H2 SO4 answer.
In the meantime, Ir-doped WO3 processes the same intrinsic exercise to Pt/C towards hydrogen evolution response. General water splitting utilizing the bi-functional Ir-doped WO3 catalyst exhibits low cell voltages of 1.56 and 1.68 V to drive the present densities of 10 and 100 mA cm-2 , respectively, with solely 16 mV decay noticed after 60 h steady electrolysis underneath the present density of 100 mA cm-2 . Structural evaluation and density useful idea calculation point out that the adjusted coordination setting of Ir inside the crystalline matrix of WO3 contributes to the excessive exercise and sturdiness.
Pulpal response to mineral trioxide combination containing phosphorylated pullulan-based capping materials
This examine aimed to judge the pulpal responses of monkey’s pulp after direct pulp capping (DPC) with the novel mineral trioxide combination containing phosphorylated pullulan-based materials (MTAPPL). Seventy-two tooth had been randomly divided into 4 teams: MTAPPL; Nex-Cem MTA (NX);
TheraCal LC (TH); and Dycal (DY). Histopathological adjustments within the pulps had been noticed at days 3, 7 and 70. On day 3, delicate inflammatory responses had been noticed within the MTAPPL, no to reasonable inflammatory responses within the TH, whereas reasonable inflammatory responses within the NX and DY. No mineralized tissue formation (MTF) was noticed in all teams.
On day 7, no or delicate inflammatory responses had been noticed in all teams. Preliminary MTF was noticed aside from DY. No irritation with full MTF together with presence of odontoblast-like cells was noticed within the MTAPPL, NX and TH teams at day 70. These findings point out that MTAPPL might be an environment friendly DPC materials.
Liquiritigenin protects towards arsenic trioxide-induced liver damage by inhibiting oxidative stress and enhancing mTOR-mediated autophagy
Liquiritigenin (LQ) has protecting results towards varied hepatotoxicities. Nonetheless, its particular position on arsenic trioxide (ATO)-induced hepatotoxicity and the associated biomolecular mechanisms stay unclear.
The aim of this examine is to discover the protecting actions of LQ on ATO-induced hepatotoxicity and its biomolecular mechanisms in mice. LQ was administered orally at 20 and 40 mg/kg per day for seven consecutive days with an intraperitoneal injection of ATO (5 mg/kg). Liver damage was induced by ATO and was alleviated by remedy with LQ as mirrored by diminished histopathological injury of liver and decreased serum ALT, AST, and ALP ranges.
The era of intracellular ROS induced by ATO was attenuated after LQ remedy. The degrees of SOD, CAT, and GSH had been elevated with LQ administration whereas MDA ranges decreased. LQ mitigated elevated TNF-α and IL-6 ranges in addition to the hepatic mitochondrial injury brought on by ATO. Furthermore, LQ upregulated the expression of LC3-II and enhanced autophagy within the liver of ATO-induced mice. Additional research indicated that LQ considerably suppressed the expression of p-PI3K, p-AKT, and p-mTOR in ATO-induced mice.
Molybdenum Cofactor Sulfurase (MOCOS) Antibody |
|||
| abx235263-100ug | Abbexa | 100 ug | EUR 577.2 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx135733 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| abx037731-100ug | Abbexa | 100 ug | EUR 469.2 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx005887 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx131326 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx131327 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx113871 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx028710-400ul | Abbexa | 400 ul | EUR 627.6 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx028710-80l | Abbexa | 80 µl | EUR 343.2 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| abx025653-400ul | Abbexa | 400 ul | EUR 627.6 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| abx025653-80l | Abbexa | 80 µl | EUR 343.2 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx036894-100ug | Abbexa | 100 ug | EUR 469.2 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx321401 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx321402 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx321947 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx322547 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx304514 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx235264-100ug | Abbexa | 100 ug | EUR 577.2 |
Recombinant Molybdenum Cofactor Synthesis 1 (MOCS1) |
|||
| 4-RPC623Hu01 | Cloud-Clone |
|
|
|
Description: Recombinant Human Molybdenum Cofactor Synthesis 1 expressed in: E.coli |
|||
Recombinant Molybdenum Cofactor Synthesis 1 (MOCS1) |
|||
| 4-RPC623Mu01 | Cloud-Clone |
|
|
|
Description: Recombinant Mouse Molybdenum Cofactor Synthesis 1 expressed in: E.coli |
|||
AAS Molybdenum Std 1000ppm in H2O |
|||
| AAMOH | Scientific Laboratory Supplies | 500ML | EUR 85.5 |
AAS Molybdenum Std 10000ppm in H2O |
|||
| AAMOM | Scientific Laboratory Supplies | 500ML | EUR 272.46 |
ICP Standard Molybdenum H2O 1000ug/ml |
|||
| PMO2A7 | Scientific Laboratory Supplies | 100ML | EUR 106.02 |
Human Molybdenum cofactor sulfurase (MOCOS) ELISA Kit |
|||
| abx250798-96tests | Abbexa | 96 tests | EUR 801.6 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (HRP) |
|||
| 20-abx304515 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (FITC) |
|||
| 20-abx304516 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (Biotin) |
|||
| 20-abx304517 | Abbexa |
|
|
Human Molybdenum Cofactor Synthesis 1 (MOCS1) Protein |
|||
| 20-abx650079 | Abbexa |
|
|
Mouse Molybdenum Cofactor Synthesis 1 (MOCS1) Protein |
|||
| 20-abx650080 | Abbexa |
|
|
Cow Molybdenum cofactor sulfurase (MOCOS) ELISA Kit |
|||
| abx516487-96tests | Abbexa | 96 tests | EUR 1093.2 |
Mouse Molybdenum cofactor sulfurase (MOCOS) ELISA Kit |
|||
| abx516489-96tests | Abbexa | 96 tests | EUR 886.8 |
Bovine MOCOS/ Molybdenum cofactor sulfurase ELISA Kit |
|||
| E0183Bo | Sunlong | 1 Kit | EUR 860.4 |
Human MOCOS(Molybdenum cofactor sulfurase) ELISA Kit |
|||
| EH1514 | FN Test | 96T | EUR 681.12 |
|
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.188 ng/ml |
|||
Human MOCOS/ Molybdenum cofactor sulfurase ELISA Kit |
|||
| E1626Hu | Sunlong | 1 Kit | EUR 726 |
Mouse Mocos/ Molybdenum cofactor sulfurase ELISA Kit |
|||
| E0967Mo | Sunlong | 1 Kit | EUR 758.4 |
ELISA kit for Human Molybdenum cofactor sulfurase |
|||
| EK3232 | SAB | 96 tests | EUR 663.6 |
|
Description: Enzyme-linked immunosorbent assay kit for quantification of Human Molybdenum cofactor sulfurase in samples from serum, plasma, tissue homogenates and other biological fluids. |
|||
Bovine Molybdenum cofactor sulfurase, MOCOS ELISA KIT |
|||
| ELI-19415b | Lifescience Market | 96 Tests | EUR 1113.6 |
Human Molybdenum cofactor sulfurase, MOCOS ELISA KIT |
|||
| ELI-20833h | Lifescience Market | 96 Tests | EUR 988.8 |
Mouse Molybdenum cofactor sulfurase, Mocos ELISA KIT |
|||
| ELI-16543m | Lifescience Market | 96 Tests | EUR 1038 |
ICP Std Molybdenum 1000ug/mL in H2O |
|||
| PMO2C1L | Scientific Laboratory Supplies | 1L | EUR 493.62 |
Kinesis Hollow Cathode Lamp Molybdenum 37mm Std |
|||
| CHR5781 | Scientific Laboratory Supplies | EACH | EUR 267.9 |
Kinesis Hollow Cathode Lamp Molybdenum 37mm unicam |
|||
| CHR5785 | Scientific Laboratory Supplies | EACH | EUR 308.94 |
Kinesis Hollow Cathode Lamp Molybdenum 37mm Varian |
|||
| CHR5787 | Scientific Laboratory Supplies | EACH | EUR 308.94 |
Kinesis Hollow Cathode Lamp Molybdenum 50mm Standard |
|||
| CHR5789 | Scientific Laboratory Supplies | EACH | EUR 351.12 |
ICP Std Molybdenum 10000ug/mL in H2O |
|||
| RPMO4B7 | Scientific Laboratory Supplies | 250ML | EUR 189.24 |
Purified GFP |
|||
| AG45-0205-Z | Immunology Consultants Laboratory | 0.1 mg | EUR 273.6 |
Ovalbumin, purified |
|||
| O705084 | Bio Basic | 1g | EUR 80.88 |
Purified Water |
|||
| H2O1 | Scientific Laboratory Supplies | 1L | EUR 15.96 |
Purified Water |
|||
| H2O10 | Scientific Laboratory Supplies | 10L | EUR 78.66 |
Purified Water |
|||
| H2O25 | Scientific Laboratory Supplies | 25L | EUR 69.54 |
Purified Water |
|||
| H2O5 | Scientific Laboratory Supplies | 5L | EUR 22.8 |
Human Molybdenum Cofactor Synthesis 2 (MOCS2) ELISA Kit |
|||
| abx381488-96tests | Abbexa | 96 tests | EUR 1093.2 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human) |
|||
| 4-PAC623Hu01 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1) |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse) |
|||
| 4-PAC623Mu01 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1) |
|||
MOCS2 Molybdenum Cofactor Synthesis 2 Human Recombinant Protein |
|||
| PROTO96033-1 | BosterBio | Regular: 10ug | EUR 380.4 |
|
Description: MOCS2 Human Recombinant produced in E. coli is a single polypeptide chain containing 224 amino acids (1-188) and having a molecular mass of 25.0 kDa.;MOCS2 is fused to a 36 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
|||
ICP Std Molybdenum 100ug/mL in 2% NH4OH |
|||
| PMO1A7 | Scientific Laboratory Supplies | 100ML | EUR 189.24 |
ICP Std Molybdenum 100ug/mL in 2% NH4OH |
|||
| PMO1C3 | Scientific Laboratory Supplies | 500ML | EUR 291.84 |
ICP Std Molybdenum 1000ug/mL in 1% HCl |
|||
| PMO2A11 | Scientific Laboratory Supplies | 100ML | EUR 107.16 |
ICP Std Molybdenum 1000ug/mL in 2% NH4OH |
|||
| PMO2B7 | Scientific Laboratory Supplies | 250ML | EUR 171 |
ICP Std Molybdenum 1000ug/mL in 2% NH4OH |
|||
| PMO2C7 | Scientific Laboratory Supplies | 500ML | EUR 310.08 |
ICP Std Molybdenum 10000ug/mL in 2% NH4OH |
|||
| PMO4A7 | Scientific Laboratory Supplies | 100ML | EUR 184.68 |
ICP Std Molybdenum 10000ug/mL in 3.5% NH4OH |
|||
| PMO4B4-500ML | Scientific Laboratory Supplies | 500ML | EUR 739.86 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), APC |
|||
| 4-PAC623Hu01-APC | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with APC. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), Biotinylated |
|||
| 4-PAC623Hu01-Biotin | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with Biotin. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), Cy3 |
|||
| 4-PAC623Hu01-Cy3 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with Cy3. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), FITC |
|||
| 4-PAC623Hu01-FITC | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with FITC. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), HRP |
|||
| 4-PAC623Hu01-HRP | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with HRP. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), PE |
|||
| 4-PAC623Hu01-PE | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with PE. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), APC |
|||
| 4-PAC623Mu01-APC | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with APC. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), Biotinylated |
|||
| 4-PAC623Mu01-Biotin | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with Biotin. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), Cy3 |
|||
| 4-PAC623Mu01-Cy3 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with Cy3. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), FITC |
|||
| 4-PAC623Mu01-FITC | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with FITC. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), HRP |
|||
| 4-PAC623Mu01-HRP | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with HRP. |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), PE |
|||
| 4-PAC623Mu01-PE | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with PE. |
|||
Mocos ELISA Kit| Mouse Molybdenum cofactor sulfurase ELISA Kit |
|||
| EF015558 | Lifescience Market | 96 Tests | EUR 826.8 |
MOCOS ELISA Kit| Bovine Molybdenum cofactor sulfurase ELISA Kit |
|||
| EF011614 | Lifescience Market | 96 Tests | EUR 826.8 |
Kinesis Hollow Cathode Lamp Molybdenum 50mm PE AAnalyst (Lumina) |
|||
| CHR5791 | Scientific Laboratory Supplies | EACH | EUR 454.86 |
Kinesis Hollow Cathode Lamp Molybdenum Chromium Cobalt 37mm Standard |
|||
| CHR5793 | Scientific Laboratory Supplies | EACH | EUR 336.3 |
Anti-SOS Purified |
|||
| 11-522-C025 | ExBio | 0.025 mg | EUR 129.6 |
Anti-SOS Purified |
|||
| 11-522-C100 | ExBio | 0.1 mg | EUR 212.4 |
Anti-PKAc Purified |
|||
| 11-523-C025 | ExBio | 0.025 mg | EUR 129.6 |
Anti-PKAc Purified |
|||
| 11-523-C100 | ExBio | 0.1 mg | EUR 212.4 |
Anti-SHIP1 Purified |
|||
| 11-524-C025 | ExBio | 0.025 mg | EUR 129.6 |
Anti-SHIP1 Purified |
|||
| 11-524-C100 | ExBio | 0.1 mg | EUR 212.4 |
Anti-SHIP1 Purified |
|||
| 11-525-C025 | ExBio | 0.025 mg | EUR 129.6 |
Anti-SHIP1 Purified |
|||
| 11-525-C100 | ExBio | 0.1 mg | EUR 212.4 |
Anti-LST1 Purified |
|||
| 11-528-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-LST1 Purified |
|||
| 11-528-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-PSMA Purified |
|||
| 11-532-C025 | ExBio | 0.025 mg | EUR 151.2 |
Anti-PSMA Purified |
|||
| 11-532-C100 | ExBio | 0.1 mg | EUR 255.6 |
Anti-CRP Purified |
|||
| 11-537-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-PSMA Purified |
|||
| 11-539-C025 | ExBio | 0.025 mg | EUR 151.2 |
Anti-PSMA Purified |
|||
| 11-539-C100 | ExBio | 0.1 mg | EUR 255.6 |
Anti-AHNAK1 Purified |
|||
| 11-540-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-AHNAK1 Purified |
|||
| 11-540-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-BRG1 Purified |
|||
| 11-541-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-BRG1 Purified |
|||
| 11-541-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-CPNE7 Purified |
|||
| 11-542-C025 | ExBio | 0.025 mg | EUR 151.2 |
Anti-CPNE7 Purified |
|||
| 11-542-C100 | ExBio | 0.1 mg | EUR 255.6 |
Anti-GRB2 Purified |
|||
| 11-554-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-GRB2 Purified |
|||
| 11-554-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-AGR3 Purified |
|||
| 11-560-C025 | ExBio | 0.025 mg | EUR 178.8 |
Anti-AGR3 Purified |
|||
| 11-560-C100 | ExBio | 0.1 mg | EUR 309.6 |
Anti-AGR3 Purified |
|||
| 11-561-C025 | ExBio | 0.025 mg | EUR 178.8 |
Anti-AGR3 Purified |
|||
| 11-561-C100 | ExBio | 0.1 mg | EUR 309.6 |
Anti-UBN1 Purified |
|||
| 11-565-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-UBN1 Purified |
|||
| 11-565-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-GFAP Purified |
|||
| 11-583-C025 | ExBio | 0.025 mg | EUR 135.6 |
Anti-GFAP Purified |
|||
| 11-583-C100 | ExBio | 0.1 mg | EUR 223.2 |
Anti-FoxP3 Purified |
|||
| 11-601-C025 | ExBio | 0.025 mg | EUR 163.2 |
Anti-FoxP3 Purified |
|||
| 11-601-C100 | ExBio | 0.1 mg | EUR 277.2 |
Anti-PRR7 Purified |
|||
| 11-617-C025 | ExBio | 0.025 mg | EUR 168 |
Anti-PRR7 Purified |
|||
| 11-617-C100 | ExBio | 0.1 mg | EUR 288 |
Anti-ABRA1 Purified |
|||
| 11-619-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-ABRA1 Purified |
|||
| 11-619-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-GRAP2 Purified |
|||
| 11-639-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-GRAP2 Purified |
|||
| 11-639-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-Notch1 Purified |
|||
| 11-651-C025 | ExBio | 0.025 mg | EUR 118.8 |
Anti-Notch1 Purified |
|||
| 11-651-C100 | ExBio | 0.1 mg | EUR 189.6 |
Anti-PDK1 Purified |
|||
| 11-659-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-ZAP70 Purified |
|||
| 11-665-C025 | ExBio | 0.025 mg | EUR 129.6 |
Anti-ZAP70 Purified |
|||
| 11-665-C100 | ExBio | 0.1 mg | EUR 212.4 |
Anti-EGFR Purified |
|||
| 11-680-C025 | ExBio | 0.025 mg | EUR 140.4 |
Anti-EGFR Purified |
|||
| 11-680-C100 | ExBio | 0.1 mg | EUR 234 |
Anti-BrdU Purified |
|||
| 11-682-C025 | ExBio | 0.025 mg | EUR 129.6 |
Anti-BrdU Purified |
|||
| 11-682-C100 | ExBio | 0.1 mg | EUR 212.4 |
Anti-Nitrotyrosine Purified |
|||
| 11-693-C025 | ExBio | 0.025 mg | EUR 189.6 |
Anti-Nitrotyrosine Purified |
|||
| 11-693-C100 | ExBio | 0.1 mg | EUR 332.4 |
Anti-Drebrin Purified |
|||
| 11-694-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-Drebrin Purified |
|||
| 11-694-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-FOLR2 Purified |
|||
| 11-696-C025 | ExBio | 0.025 mg | EUR 118.8 |
Anti-FOLR2 Purified |
|||
| 11-696-C100 | ExBio | 0.1 mg | EUR 189.6 |
Anti-PCLO Purified |
|||
| 11-698-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-PCLO Purified |
|||
| 11-698-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-OPAL1 Purified |
|||
| 11-699-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-OPAL1 Purified |
|||
| 11-699-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-CLIC5 Purified |
|||
| 11-701-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-CLIC5 Purified |
|||
| 11-701-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-LARGE1 Purified |
|||
| 11-702-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-LARGE1 Purified |
|||
| 11-702-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-SCIMP Purified |
|||
| 11-704-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-SCIMP Purified |
|||
| 11-704-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-TFG Purified |
|||
| 11-709-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-TFG Purified |
|||
| 11-709-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-PDE8A Purified |
|||
| 11-710-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-PDE8A Purified |
|||
| 11-710-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-NCK1 Purified |
|||
| 11-711-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-NCK1 Purified |
|||
| 11-711-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-DLL4 Purified |
|||
| 11-717-C025 | ExBio | 0.025 mg | EUR 103.2 |
Anti-DLL4 Purified |
|||
| 11-717-C100 | ExBio | 0.1 mg | EUR 157.2 |
Anti-RLTPR Purified |
|||
| 11-718-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-RLTPR Purified |
|||
| 11-718-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-NR2F6 Purified |
|||
| 11-719-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-NR2F6 Purified |
|||
| 11-719-C100 | ExBio | 0.1 mg | EUR 244.8 |
Anti-ARHGEF4 Purified |
|||
| 11-723-C025 | ExBio | 0.025 mg | EUR 129.6 |
Anti-ARHGEF4 Purified |
|||
| 11-723-C100 | ExBio | 0.1 mg | EUR 212.4 |
In conclusion, our findings present that LQ protects towards ATO-induced hepatotoxicity as a consequence of its antioxidant and anti inflammatory actions and enhancement of autophagy mediated by the PI3K/AKT/mTOR signaling pathway in mice.
